ストックスクリーナーアプリを入手
15.55
3.12%
-0.50
アフターアワーズ：
15.55
Biohaven Ltd (BHVN) 最新ニュース
Why Wall Street Is Growing More Cautious on Biohaven (BHVN) - Yahoo Finance
BHVNBiohaven Ltd Latest SEC Filings - Finviz
Biohaven Shares Drop 9.8% to $14.28 - Intellectia AI
Biohaven (BHVN) Insider Trading Activity 2026 - MarketBeat
Does Advancing Opakalim and BHV-1300 to Pivotal Trials Change The Bull Case For Biohaven (BHVN)? - simplywall.st
Biohaven completes enrollment in opakalim epilepsy trial - Investing.com
Biohaven completes enrollment in opakalim epilepsy trial By Investing.com - Investing.com Nigeria
Biohaven completes enrollment in focal epilepsy drug trial - StreetInsider
Biohaven Completes Enrollment in RISE 3 Pivotal Focal Epilepsy Study with Opakalim, a Selective Kv7.2/7.3 Activator - PR Newswire
Biohaven Shares Down as Phase 3 Trial Concerns Trigger Downgrade at BofA - Moomoo
What's Going On With Biohaven Stock Monday?Biohaven (NYSE:BHVN) - Benzinga
Biohaven (BHVN) Shares Decline Nearly 10% Amid Market Fluctuatio - GuruFocus
BHVN Downgraded by B of A Securities -- Price Target Lowered to $11 - GuruFocus
Biohaven begins phase 3 trial of BHV-1300 for Graves’ disease - Investing.com
BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - marketscreener.com
Biohaven Doses First Patient in Phase 3 Trial of BHV-1300 for Graves' Disease - marketscreener.com
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Session - Benzinga
Update: BofA Securities Downgrades Biohaven to Underperform From Neutral, Trims Price Target to $11 From $12 - Moomoo
BofA Securities Downgrades Biohaven to Underperform From Neutral, $11 Price Target - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns By Investing.com - Investing.com Australia
BofA Securities Downgrades Biohaven(BHVN.US) to Sell Rating, Cuts Target Price to $11 - Moomoo
BofA downgrades Biohaven stock on epilepsy drug concerns - Investing.com
Biohaven's BHV-1300 targets the root cause of Graves' disease in Phase 3 - Stock Titan
Biohaven Advances a New Class of Precision Immunology Therapies: First MoDE Extracellular Protein Degrader, BHV-1300, Begins Phase 3 Pivotal Trial in Graves' Disease - Sahm
BHVN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
BHVN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
BHVN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Biohaven Ltd (BHVN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Deutsche Bank Adjusts Biohaven Price Target to $20 From $15, Maintains Buy Rating - Moomoo
Biohaven Ltd (BHVN) Stock Price, Quote, News & History - Benzinga
Deutsche Bank Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $20 - Moomoo
Biohaven Ltd. Actuals & Estimates (NYSE:BHVN) - TradingView
ZH6 Forecast — Price Target — Prediction for 2027 - TradingView
BHVN Forecast — Price Target — Prediction for 2027 - TradingView
Biohaven's Troriluzole Could Drive Potential Upside if the Company Overcomes Regulatory Hurdles, RBC Says - marketscreener.com
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Raymond James Maintains Biohaven(BHVN.US) With Buy Rating - Moomoo
Biohaven (BHVN) Is Up 22.2% After Advancing Multiple Immunology And Oncology Candidates To Pivotal Trials - Sahm
Behavioral Patterns of BHVN and Institutional Flows - Stock Traders Daily
Biohaven (BHVN) Climbs 14% Higher Ahead of New Clinical Trials - Insider Monkey
Could Biohaven’s Expanding Pipeline Boost Russell 1000 Momentum? - Kalkine Media
Biohaven (BHVN) Stock Looks Rich After Pivotal Trial Plans Lift Shares - simplywall.st
Biohaven Ltd (BHVN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biohaven Ltd (BHVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biohaven Ltd (BHVN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biohaven Ltd (BHVN) Institutional Confidence - TradingKey
Biohaven Ltd (BHVN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biohaven Ltd. (BHVN) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
BIOHAVEN LTD (BHVN) Stock Chart - ChartMill
Biohaven: Upgrading To Buy On Protein Degraders Pivotal Study Initiations - Seeking Alpha
CCORF Maintains Biohaven(BHVN.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Biohaven Ltd (BHVN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Biohaven Ltd (BHVN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biohaven Ltd (BHVN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline Updates - Insider Monkey
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):